DRTS · Alpha Tau Medical Ltd. · Stock research

Current Thesis

The dated binary the prior note was built around has resolved, and it resolved in the company's favour. On 2026-07-21 Alpha Tau presented complete top-line data from Alpha DaRT plus pembrolizumab in elderly locally-advanced/metastatic head-and-neck squamous cell carcinoma: a 100% objective response rate across nine evaluable patients, 18.2-month median overall survival, mild device-related side effects only, and enrollment stopped early for success under the study's Simon two-stage adaptive design. What did not happen is a new leg. On the adjusted daily series used here the 2026-08-07 close is $13.14 against a $13.57 52-week high — 3.2% below it — with RSI(14) at 47.0 and a three-month return of +54.4%. Simply Wall St's 2026-08-03 piece framed the reaction directly: shares down 5.7% into that date despite the early-stop success. The name is now a funded issuer sitting in a catalyst gap, two sessions from a Q2 print (2026-08-10, before the open) that resolves cash and timing rather than efficacy, with the ReSTART cutaneous squamous cell carcinoma pivotal top-line — guided to late H2 2026 and still not calendared — as the next event with registrational weight.

Bullish and bearish views on Alpha Tau Medical Ltd.

The model's bull view on Alpha Tau Medical Ltd. (DRTS), in brief: The July readout cleared its own bar and then some. The bear view: Nine evaluable patients is a signal, not a registration. Both cases follow in full.

Bull Case

• The July readout cleared its own bar and then some. 2026-07-21: 100% ORR across nine evaluable patients, 18.2-month median OS, only mild device-related adverse events, enrollment halted early for success under a Simon two-stage design. Historical benchmarks for this elderly, platinum-ineligible HNSCC population are materially worse; the combination arm is now the strongest single efficacy datapoint in the file.
• Sell-side did not fade it. HC Wainwright reiterated Buy with a $15 price target on 2026-07-16 and again on 2026-07-22, the session after the data. Aggregated marks tracked by ChartMill/MarketBeat sit near $14.48 across 11 analysts (retrieved 2026-08-08), both above the 2026-08-07 close of $13.14.
• The regulatory path is in motion, not aspirational. First Pre-Market Approval module submitted to FDA for recurrent cSCC on 2026-01-05; ReSTART pivotal enrollment completed 2026-05-08; first immunocompromised recurrent-cSCC patient treated in the ADMIRE study at Banner MD Anderson on 2026-07-15. A modular PMA lets review advance in pieces rather than waiting on one dossier.
• Commercial validation is priced into the cap table. Tolmar US prostate agreement, 2026-06-03: $35M upfront including $20M of equity struck at $11.99, up to $161.5M in prostate milestones, 20-year US exclusivity, Tolmar funding 60% of net-sales supply cost, plus a bladder option.
• Funding is not the near-term constraint. $80.2M cash reported with Q1 on 2026-05-18 plus roughly $35M of Tolmar proceeds against a stated ~$22–25M quarterly burn — enough to carry past the ReSTART readout without a raise being forced by the calendar.

Bear Case

• Nine evaluable patients is a signal, not a registration. The 2026-07-21 dataset is small, single-arm and in a selected elderly population. The pivotal question is ReSTART in cSCC, and nothing in the HNSCC combination result de-risks that endpoint.
• Good news stopped producing new highs. The stock did not take out its 52-week high on the podium data; Simply Wall St recorded a 5.7% decline into 2026-08-03 in spite of the early-stop success. RSI(14) at 47.0 on 2026-08-07 with price only 3.2% under the high describes a range, not a trend.
• Still pre-revenue with widening losses. Q1 2026 (2026-05-18): net loss $22.9M, EPS -$0.26 against -$0.12 consensus. Consensus for the 2026-08-10 Q2 print is -$0.14 EPS on $0.144M of revenue (MarketBeat, 2026-08-03).
• Insiders sold into the July advance. CFO Raphi Levy disposed of 2,127 shares (~$27.7k) on 2026-07-02 and 2,270 shares (~$31.8k) on 2026-07-07. Small and plausibly programmatic, but the direction was out while the tape made highs.
• Headroom to published marks is thin. At $13.14 the close sits roughly 12% under HC Wainwright's $15 and about 10% under the ~$14.48 aggregate — the marks are not where the fresh incremental bid usually comes from.
• A thin, gap-prone US-listed Israeli small cap. Low average daily volume around 1M shares; the +17.9% single-session move on the 2026-06-23 Hadassah glioblastoma treatment showed how far one headline moves this book in either direction.

Setup & Price Structure

Last completed daily close $13.14 (2026-08-07); 52-week high $13.57 on the adjusted series; -3.2% from that high; three-month return +54.4%; RSI(14) 47.0. The structure built in June and July is intact: the $11.99 Tolmar equity strike (2026-06-03) and the $11.62 prior 52-week high were reclaimed on the 2026-06-23 GBM headline and have not been surrendered since. Below them the reference is the ~$8.95 pre-deal base.

Life-cycle: MATURING. The narrative is well known to its holder base, still working on price (+54.4% over three months), and no longer expanding on new information. What dates the label: the 2026-07-21 podium delivered an unambiguously positive top-line and did not produce a new 52-week high; the only sell-side response in the following two weeks was a reiteration at an unchanged $15 (2026-07-22); and the company newsroom has published nothing since 2026-07-15/07-21. Fresh attention has stopped arriving while the price holds.

Crowding and positioning observables — stated as observed, without a verdict: retail-facing coverage clustered around the move (Simply Wall St pieces 2026-07-06 and 2026-08-03, multiple Benzinga items 2026-07-15 through 2026-07-22); the close sits 3.2% under the 52-week high while RSI(14) reads 47.0, i.e. momentum has drained without price giving way; an earnings date falls two sessions after the price basis (2026-08-10, pre-market); two CFO sales printed into the July highs (2026-07-02, 2026-07-07); and the June financing issued $20M of stock at $11.99, placing a known institutional cost basis directly beneath the current range.

Catalyst Calendar (next 30 days)

• 2026-08-10 (confirmed, before market open) — Q2 2026 financial results and corporate update. Consensus -$0.14 EPS on $0.144M revenue (MarketBeat, 2026-08-03). What it resolves: cash after the Tolmar inflow, the burn rate against the stated 2–3 year runway, and any tightening of ReSTART top-line timing.
• ~2026-09-10 (est.) — no company-dated clinical or regulatory event is scheduled between the Q2 print and mid-September on the current newsroom calendar. This is an open window; treat any dated item appearing in it as new information.
• ~2026-12-31 (est.) — ReSTART pivotal cSCC top-line, guided to late H2 2026, still without a specific date. Outside the 30-day window and the largest single value event in the file.

What Would Change Our Mind

The structure that carries this read is the shelf a partner paid for: $20M of equity struck at $11.99 on 2026-06-03, sitting just under the reclaimed $11.62 prior high. Losing that band would say the June–July advance was a headline sequence rather than a re-rating, and would point back toward the ~$8.95 pre-deal base. The gradeable version: a daily close below $11.99. Secondary conditions, either of which would break the frame independently of price — the 2026-08-10 Q2 update pushing ReSTART cSCC top-line out of 2026 and into next year; the theme flipping to SATURATED if the ~$14.48 aggregate and the $15 HC Wainwright mark are reached without an accompanying estimate revision; or an equity raise disclosed despite the ~$115M pro forma cash position, which would contradict the funding argument outright. On the other side, a weekly close above $13.57 on a dated ReSTART or PMA item would re-date the narrative as ACCELERATING.

Correlation Notes

Alpha DaRT is a Ra-224 diffusing-alpha device regulated through the PMA device pathway, so read-through from systemic radioligand names (Lantheus, Telix, the Pluvicto franchise) is limited to sentiment; isotope supply and radiopharmacy logistics headlines that move those names do not mechanically apply here — that is an inference from the regulatory pathway, not a measured beta. The measured driver is idiosyncratic: the 2026-06-23 Hadassah treatment (+17.9%) and the 2026-07-21 podium each moved the stock independently of the tape. As a sub-$1.5B pre-revenue name the shares carry the risk appetite of small-cap biotech (XBI complex) more than any oncology-specific factor, and as an Israeli-domiciled issuer they inherit the geopolitical risk premium applied to that cohort. Tolmar is private, so there is no listed instrument through which the partnership's progress prices independently — the only place that deal marks is DRTS itself.